StoneWise's MolVortex early-discovery agent lands in Lianyungang, opening to local pharma and academia via an AI tool marketplace

StoneWise's small-molecule early-discovery agent MolVortex has completed local deployment on Lianyungang's "AI + medicine" public service platform and become one of the platform's core ecosystem partners for drug discovery and molecular design. Platform head Xu Qiang framed the backdrop: drug R&D takes long and costs much, and small and mid-sized pharma companies commonly face high R&D entry barriers, difficulty landing AI, and pressure to build their own compute and data systems. The platform is built on a "two middle platforms, one marketplace, one network, one hub" architecture supported by shared compute and compliant pharmaceutical AI datasets, so a company logs into a unified portal and calls AI engines and high-quality data assets on demand.

MolVortex is built on a family of models including a general large language model, StoneWise's in-house 2D generative model, a multimodal AI 3D molecular generative model and an electron-density-based molecular generative model, coordinating multiple specialized sub-agents. The combination covers target research, pocket analysis, molecule generation and dynamics evaluation, spanning the early-discovery workflow from hit to preclinical candidate. StoneWise says it embeds medicinal-chemistry judgment into system design, forming domain know-how across molecule generation, binding assessment and druglikeness analysis, and stresses automatic task handoff and reuse of results across stages to meet pharma's need for traceable, explainable and reviewable early research.

The report covers the cooperation agreement between StoneWise and Jiangsu XinHailian Group, the launch of Lianyungang's "AI + medicine" public service platform, and MolVortex's local deployment and marketplace listing on that platform; it is aimed at researchers and engineers following AI pharma deployment and regional public service platforms. StoneWise says it will keep improving innovative drug R&D modules and support long-term platform operation, with capabilities extending further to Jiangsu and neighboring regions.

The announcement gives no actual call volume, number of served companies or any R&D outcome metric for MolVortex on the platform; the platform's cost and efficiency benefit for companies rests on the platform head's description of pain points and the architecture design, without operating data.